Monoclonal gammopathy of undetermined significance (MGUS) is the most common plasma cell proliferative disorder, with a prevalence >3% in the general population older than 50 years. The prevalence of MGUS increases with age, from 1.7% in those 50 to 59 years old to >5% in those older than 70 years. MGUS is associated with an increased risk of multiple myeloma or related malignancies at a rate of 1% per year. Recently, it has been proposed to add the measurement of N-terminal B-type natriuretic peptide (NT-proBNP) to traditional tests used for monitoring MGUS to timely detect initial cardiac amyloid involvement. In this report, we present the case of a patient with MGUS who was followed at our center since February 2006. During the follow-up, the progressive increase of NT-proBNP and cardiac troponin I suggested the onset of primary systemic light-chain amyloidosis (AL) with cardiac involvement. The subsequent investigations led to the definition of the cause of heart dysfunction. This case highlights the importance of the regular follow-up of MGUS and the contribution of cardiac biomarkers in improving the clinical efficacy of monitoring.
|Translated title of the contribution||A case of monoclonal gammopathy solved with cardiac biomarkers|
|Number of pages||4|
|Publication status||Published - Jun 2011|
ASJC Scopus subject areas
- Clinical Biochemistry
- Biochemistry, medical
- Medical Laboratory Technology